scholarly journals Electronic and Magnetic Communication in Mixed-Valent and Homovalent Ruthenium Complexes Containing Phenylcyanamide Type Bridging Ligands

2007 ◽  
Vol 129 (5) ◽  
pp. 1434-1444 ◽  
Author(s):  
Muriel Fabre ◽  
Jacques Bonvoisin

2011 ◽  
Vol 50 (21) ◽  
pp. 10581-10591 ◽  
Author(s):  
Neus Vilà ◽  
Guy Royal ◽  
Frédérique Loiseau ◽  
Alain Deronzier


2020 ◽  
Vol 27 (22) ◽  
pp. 3735-3752 ◽  
Author(s):  
Si-Qi Zhang ◽  
Li-Hua Gao ◽  
Hua Zhao ◽  
Ke-Zhi Wang

Ruthenium complexes have stood out by several mononuclear complexes which have entered into clinical trials, such as imidazolium [trans-RuCl4(1H-imidazole)(DMSO-S)] (NAMI-A) and ([Ru(II)(4,4'-dimethyl-2,2'-bipyridine)2-(2(2'-,2'':5'',2'''-terthiophene)-imidazo[4,5-f] [1,10]phenanthroline)] 2+) (TLD-1433), opening a new avenue for developing promising ruthenium-based anticancer drugs alternative to Cisplatin. Polynuclear ruthenium complexes were reported to exhibit synergistic and/or complementary effects: the enhanced DNA structural recognition and DNA binding as well as in vitro anticancer activities. This review overviews some representative polynuclear ruthenium complexes acting as DNA structural probes, DNA binders and in vitro anticancer agents, which were developed during last decades. These complexes are reviewed according to two main categories of homo-polynuclear and hetero-polynuclear complexes, each of which is further clarified into the metal centers linked by rigid and flexible bridging ligands. The perspective, challenges and future efforts for investigations into these exciting complexes are pointed out or suggested.





1996 ◽  
Vol 35 (21) ◽  
pp. 6245-6253 ◽  
Author(s):  
Gabriele Albertin ◽  
Stefano Antoniutti ◽  
Alessia Bacchi ◽  
Emilio Bordignon ◽  
Giancarlo Pelizzi ◽  
...  




2013 ◽  
Vol 52 (19) ◽  
pp. 11060-11066 ◽  
Author(s):  
Mohommad M. R. Choudhuri ◽  
Wolfgang Kaim ◽  
Biprajit Sarkar ◽  
Robert J. Crutchley




Sign in / Sign up

Export Citation Format

Share Document